TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mortality from Treatment
Endpoint domain: Mortality/survival
Primary endpoint: Morbidity from Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Cerebrospinal Fluid (CSF) Leak
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of endometrial preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibromyalgia Impact Questionnaire (FEA)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of bone mineral density loss at the total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction of bone mineral density loss at the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual Analog Scale (VAS) - Dyspnea Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with DLT in each dose group within 2 cycles (42 days) after the first trial administration
Endpoint domain: Adverse events/effects
Primary endpoint: Development of Catheter related blood stream infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Volume reduction in cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of antalgic therapy (mg)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to surgical resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Participants Who Achieve an ASAS 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Harris Hip Score (mHHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of grade 2 or more dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Sleep quality measured by Polysomnography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F. Prausnitzii abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of ICU admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent time in range of 70-180mg/dL (%TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in opioid dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of the acellular pertussis vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oocyte in-vitro maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Oocyte activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) for Fedratinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) for Fedratinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial literacy learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocabulary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-calculation skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Achieving ACR 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes on vertigo symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma amyloid-beta-40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma amyloid-beta-42
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past month marijuana use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past month cigarette smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Spastic Paraplegia Rating Scale (SPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MASEI ultrasound enthesitis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Successful implantation of the TRICENTO bioprosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adherence to heart failure medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants screened positive for anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant acceptability of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of Left Ventricular Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of volunteers with solicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of volunteers with an attack rate of ≥60%
Endpoint domain: Adverse events/effects
Primary endpoint: visual analogue scale (VAS) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mc-Gill Melzack Pain Questionnaire change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flexion endurance test change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar proprioception (joint repositioning error of lumbar spine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Cigarettes Smoked Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale for Tinnitus (VAS-tinnitus)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: School Situations Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Home Situations Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Attention and Executive Function Rating Inventory -Preschool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in brain NAD+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in brain redox state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: neurodegeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuroplasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid rescue medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quantity of COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Local regrowth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Personal CGM Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of AAU Readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Emergency Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Consultations of Other Medical Providers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants with AEs leading to study treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Patient related outcomes (PROMIS, HOOS, KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: maximum tolerated dose (MTD) or maximum applicable dose (MAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Response by SARS-CoV-2 Qualitative IgG Antibody Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 12-month OS rate
Endpoint domain: Mortality/survival
Primary endpoint: Radiographic Bone Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days for complete re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Eligible Patients Who Enroll and Participate in the Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants who Have High Satisfaction with the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hopkins Symptom Checklist-25 (change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Physical Performance Battery (change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late-Life Function and Disability Instrument (LLFDI) - functional component (change)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in fat mass index Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of plasma interleukin-10 to tumor necrosis factor-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal third trimester pharmacokinetic measures (AUC and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial tenofovir levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placental transfer (cord blood tenofovir levels, placental tissue tenofovir levels, and amniotic fluid tenofovir levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who pick up the phone call
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Minutes of Moderate Physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of cooled radiofrequency in reducing knee osteoarthritis pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of time with sensor glucose measurements between 3.9 and 10.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with HIV viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fractional Excretion of Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ki-67 molecular
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAZ (WWTR1) TAZ expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximal pelvic floor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor control of the lumbopelvic area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: [18F]F-AraG uptake signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length from ADC to anterior cartilage margin (L1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: length from ADC to the center of femoral tunnel (l1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: length from the center of femoral tunnel to the distal cartilage margin (D1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of patients with death or disability
Endpoint domain: Mortality/survival
Primary endpoint: Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Core Outcome Measures Index (COMI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hemoglobin Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: five kilometer run time trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Unpleasantness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of taking OCTA images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with depressive or anxiety disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Exercise intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants without virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ethinyl estradiol area under the concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiotherapy adapted Engel classification (RAEC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speed endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Extremity Functional
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to eCPR Decision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with laboratory examination abnormity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with virus shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum or plasma levels of vitamins and minerals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycemic control using blood glucose measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycemic control using HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycemic control evaluated by Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycemic control evaluated by HOMA-IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycemic control evaluated by HOMA-β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Outcomes Event Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Report Visual Analog Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Report Visual Analog Anxiety Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Self-Report Visual Analog Stress Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total ICU time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypolipidaemic effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Spanish Rey Auditory Verbal Learning Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Escala Wechsler de Inteligencia Para Adultos-IV (WAIS-IV) Retención de dígitos
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Escala Wechsler de Inteligencia Para Adultos-IV (WAIS-IV) Claves subtest
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Color Trails 1 and 2
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: FAS
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Animal Naming
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intraoperative blood pressure management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative blood pressure management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Required blood transfusions per participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Speech categorization accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events and favorable events
Endpoint domain: Adverse events/effects
Primary endpoint: Orotracheal intubation and invasive mechanical ventilation at 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of MB and CRNMB
Endpoint domain: Mortality/survival
Primary endpoint: symptom relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physical Function using Clinician Reported Outcomes (ClinRo)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physical Function using Performance Outcome 6-Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with at least 1 dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing treatment-emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Functional recovery of the shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-bleaching sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Hyperfibrinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Category Fluency from Baseline to 1-week Post-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Category Fluency from Baseline to 2-months Post-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in COWAT from Baseline to 1-week Post-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in COWAT from Baseline to 2-months Post-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Menstrual pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of individuals with stable or improved cardiac fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of individuals with stable or improved Transforming growth factor (TGF-β1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse rate per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure rate, mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SpO2 value of the patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Heart Rate (Heart Pounding)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Analogue Scale change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Shoulder function change_1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRQoL change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fibrosis of the breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cosmetic outcome (9-item questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cosmetic outcome (BCCT.core software)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Daily psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction rate of adverse events in patient
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of ESA hyporesponsive events
Endpoint domain: Adverse events/effects
Primary endpoint: Changing patterns of brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FIT Completion at 7 Days Post-FIT Test Order
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: FIT Completion at 14 Days Post-FIT Test Order
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: FIT Completion at 21 Days Post-FIT Test Order
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall experiences and perspectives of women with ADHD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: E-cigarette Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Susceptibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean pre-operative anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing